Press coverage about OraSure Technologies (NASDAQ:OSUR) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 47.4281526500049 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of brokerages recently issued reports on OSUR. TheStreet upgraded shares of OraSure Technologies from a “c+” rating to a “b” rating in a report on Thursday, August 9th. Stephens cut shares of OraSure Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, July 16th. ValuEngine upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, July 6th. Zacks Investment Research cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Finally, BidaskClub cut shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $21.33.

OSUR traded down $0.32 during trading on Friday, reaching $15.69. The company had a trading volume of 452,173 shares, compared to its average volume of 441,521. The firm has a market cap of $971.44 million, a P/E ratio of 30.76, a PEG ratio of 3.53 and a beta of 1.61. OraSure Technologies has a 12 month low of $12.86 and a 12 month high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, August 8th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.03. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The firm had revenue of $43.60 million for the quarter, compared to analyst estimates of $42.24 million. During the same period in the prior year, the firm posted $0.09 earnings per share. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. research analysts forecast that OraSure Technologies will post 0.36 EPS for the current year.

In other OraSure Technologies news, Director Charles W. Patrick sold 8,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $16.29, for a total transaction of $130,320.00. Following the sale, the director now directly owns 54,298 shares of the company’s stock, valued at $884,514.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.90% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Article: Are Wall Street analysts’ stock ratings worth following?

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with's FREE daily email newsletter.